Scout Investments, Inc. Biomarin Pharmaceutical Inc Transaction History

Scout Investments, Inc.

$3.78 Billion
Q1 2024

A detailed history of Scout Investments, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Scout Investments, Inc. holds 675,868 shares of BMRN stock, worth $55 Million. This represents 1.56% of its overall portfolio holdings.

Number of Shares

675,868

Previous 791,625 14.62%

Holding current value

$55 Million

Previous $76.3 Million 22.66%

% of portfolio

1.56%

Previous 2.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$83.81 - $99.0 $9.7 Million - $11.5 Million	-115,757 Reduced 14.62%	675,868 $59 Million
Q4 2023 Feb 13, 2024	SELL	$76.22 - $98.51 $8.49 Million - $11 Million	-111,441 Reduced 12.34%	791,625 $76.3 Million
Q3 2023 Nov 09, 2023	SELL	$85.07 - $94.48 $2.68 Million - $2.98 Million	-31,529 Reduced 3.37%	903,066 $79.9 Million
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $30.9 Million - $35.8 Million	356,753 Added 61.74%	934,595 $81 Million
Q1 2023 May 11, 2023	BUY	$87.74 - $117.27 $2.31 Million - $3.09 Million	26,378 Added 4.78%	577,842 $56.2 Million

Q4 2022 Jan 23, 2023	BUY	$80.93 - $108.63 $8.59 Million - $11.5 Million	106,137 Added 23.83%	551,464 $0
Q3 2022 Oct 18, 2022	SELL	$82.16 - $96.94 $16.1 Million - $19 Million	-195,744 Reduced 30.53%	445,327 $37.8 Million
Q2 2022 Jul 15, 2022	SELL	$71.48 - $86.85 $663,977 - $806,749	-9,289 Reduced 1.43%	641,071 $53.1 Million
Q1 2022 Apr 14, 2022	BUY	$74.28 - $92.69 $8.51 Million - $10.6 Million	114,611 Added 21.39%	650,360 $50.1 Million
Q4 2021 Jan 14, 2022	BUY	$71.72 - $91.47 $8.28 Million - $10.6 Million	115,432 Added 27.46%	535,749 $47.3 Million
Q3 2021 Oct 13, 2021	SELL	$74.77 - $85.47 $14.8 Million - $16.9 Million	-198,005 Reduced 32.02%	420,317 $32.5 Million
Q2 2021 Jul 23, 2021	BUY	$75.51 - $84.79 $10.4 Million - $11.7 Million	137,945 Added 28.72%	618,322 $51.6 Million
Q1 2021 Apr 09, 2021	BUY	$74.73 - $90.69 $13.2 Million - $16 Million	176,955 Added 58.32%	480,377 $36.3 Million
Q4 2020 Jan 12, 2021	SELL	$72.61 - $90.2 $4.24 Million - $5.27 Million	-58,406 Reduced 16.14%	303,422 $26.6 Million
Q3 2020 Oct 13, 2020	BUY	$71.87 - $131.03 $6.18 Million - $11.3 Million	86,032 Added 31.19%	361,828 $27.5 Million
Q2 2020 Jul 14, 2020	SELL	$79.55 - $124.22 $1.73 Million - $2.69 Million	-21,686 Reduced 7.29%	275,796 $34 Million
Q1 2020 Apr 16, 2020	SELL	$71.37 - $96.85 $7.4 Million - $10 Million	-103,665 Reduced 25.84%	297,482 $25.1 Million
Q4 2019 Jan 08, 2020	BUY	$64.27 - $86.37 $18.3 Million - $24.6 Million	285,203 Added 245.98%	401,147 $33.9 Million
Q3 2019 Oct 08, 2019	SELL	$67.4 - $85.11 $34,980 - $44,172	-519 Reduced 0.45%	115,944 $7.82 Million
Q2 2019 Jul 10, 2019	SELL	$80.35 - $93.9 $6.59 Million - $7.7 Million	-82,052 Reduced 41.33%	116,463 $9.98 Million
Q1 2019 Apr 12, 2019	BUY	$84.2 - $98.62 $696,502 - $815,784	8,272 Added 4.35%	198,515 $17.6 Million
Q4 2018 Jan 11, 2019	BUY	$80.14 - $106.07 $3.18 Million - $4.21 Million	39,710 Added 26.38%	190,243 $16.2 Million
Q3 2018 Oct 15, 2018	SELL	$93.92 - $105.72 $5.97 Million - $6.72 Million	-63,566 Reduced 29.69%	150,533 $14.6 Million
Q2 2018 Jul 16, 2018	BUY	$76.01 - $99.03 $9.06 Million - $11.8 Million	119,185 Added 125.57%	214,099 $20.2 Million
Q1 2018 May 09, 2018	SELL	$77.67 - $92.63 $1.58 Million - $1.89 Million	-20,365 Reduced 17.67%	94,914 $7.7 Million
Q4 2017 Feb 14, 2018	SELL	$80.76 - $95.13 $12.2 Million - $14.4 Million	-151,456 Closed	0 $0
Q3 2017 Nov 03, 2017	BUY	$80.6 - $94.95 $5.36 Million - $6.31 Million	66,470 Added 78.21%	151,456 $14.1 Million
Q2 2017 Aug 08, 2017	BUY	N/A	84,986	84,986 $7.72 Million

Others Institutions Holding BMRN

# of Institutions

623

Shares Held

181M

Call Options Held

1.73M

Put Options Held

1.73M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Scout Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Scout Investments, Inc. with notifications on news.

Account

Scout Investments, Inc. Biomarin Pharmaceutical Inc Transaction History